Guideline for the management of COVID-19 patients during hospital admission in a non-intensive care setting

References

• Oczkowski S, Levy MM, Derde L, et al. Surviving sepsis campaign : guidelines on the management of critically Ill adults with coronavirus disease 2019 (COVID-19). Authors Intensive Care Medicine (ICM) Crit Care Med. 2020;2019;1–3.
   Google Scholar
• World Health Organization (WHO). Health systems respond to COVID-19 technical guidance #2 creating surge capacity for acute and intensive care recommendations for the WHO European Region (6 April 2020), The World Health Organisation; 2020.
   Google Scholar
• Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 PATIENTS INFECTED WITH SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. Jama. 2020;1–15. DOI:10.1001/jama.2020.5394.
   Web of Science ®Google Scholar
• Spychalski P, Błażyńska-Spychalska A, Kobiela J. Correspondence Estimating case fatality rates of COVID-19. Lancet. 2020;3099:19–20.
   Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
   PubMed Web of Science ®Google Scholar
• Laursen CB, Rahman NM, Volpicelli G, editor. Thoracic Ultrasound. Eur Respir Soc. 2018. DOI:10.1183/2312508X.erm7918
   Google Scholar
• Peng QY, Wang XT, Zhang LN, et al. Findings of lung ultrasonography of novel corona virus pneumonia during the 2019 – 2020 epidemic. Intensive Care Med. 2020;6–7. DOI:10.1007/s00134-020-05996-6
   Web of Science ®Google Scholar
• World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Vol. 2019, The World Health Organisation; 2020. p. 12.
   Google Scholar
• O’Driscoll BR, Howard LS, Earis J, et al. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017;72:ii1–90.
   PubMed Web of Science ®Google Scholar
• Chu DK, Kim LHY, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. 2018;391:1693–1705.
   PubMed Web of Science ®Google Scholar
• Girardis M, Busani S, Damiani E, et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit the oxygen-ICU randomized clinical trial. J Am Med Assoc. 2016;316:1583–1589.
   PubMed Web of Science ®Google Scholar
• Sundhedsstyrelsen. National Klinisk Retningslinje for iltbehandling til den akut syge voksne patient. 2019.
   Google Scholar
• Barrot L, Asfar P, Mauny F, et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. N Engl J Med. 2020;382:999.
   PubMed Web of Science ®Google Scholar
• López-Campos JL, Soler-Cataluña JJ, Miravitlles M. global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2019 report: future challenges. Arch Bronconeumol. 2020;56:65–67.
   Web of Science ®Google Scholar
• Messika J, Ben AK, Gaudry S, et al. Use of high-flow nasal cannula oxygen therapy in subjects with ARDS: a 1-year observational study. Respir Care. 2015;60:162–169.
   PubMed Web of Science ®Google Scholar
• Hui DS, Chow BK, Lo T, et al. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J. 2019;53. DOI:10.1183/13993003.02339-2018.
   Web of Science ®Google Scholar
• Hui DSC, Chan MTV, Chow B. Aerosol dispersion during various respiratory therapies: a risk assessment model of nosocomial infection to health care workers. Hong Kong Med J. 2014;20:9–13.
   Google Scholar
• Roca O, Caralt B, Messika J, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med. 2019;199:1368–1376.
   PubMed Web of Science ®Google Scholar
• Ruiqiang Z, Ming H, Care I. Norms and advice expert advice on procedure of respiratory therapy for severe novel coronavirus pneumonia. Chin J Crit Care Intensive Care Med. 2020. DOI:10.3877/cma.j..2096-1537.2020.E001
   Google Scholar
• Denehy L, Berney S. The use of positive pressure devices by physiotherapists. Eur Respir J. 2001;17:821–829.
   Web of Science ®Google Scholar
• Xu XP, Zhang XC, Hu SL, et al. Noninvasive ventilation in acute hypoxemic nonhypercapnic respiratory failure: a systematic review and meta-analysis. Crit Care Med. 2017;45:e727–33.
   PubMed Web of Science ®Google Scholar
• Italian Thoracic Society and Italian Respiratory Society. Managing the Respiratory care of patients with COVID-19; 2020.p. 1–17.
   Google Scholar
• Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50. DOI:10.1183/13993003.02426-2016.
   Google Scholar
• Hansen EF, Fabricius P, Titlestad IL, et al. KOL - exacerbation og NIV. Lungemedicinsk Selsk 2017:1–5.
   Google Scholar
• Simonds AK, Hanak A, Chatwin M, et al. Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. Health Technol Assess (Rockv). 2010;14:131–172.
   PubMed Web of Science ®Google Scholar
• Davies A, Thomson G, Walker J, et al. A review of the risks and disease transmission associated with aerosol generating medical procedures. J Infect Prev. 2009;10:122–126.
   Google Scholar
• McGrath JA, O’Sullivan A, Bennett G, et al. Investigation of the quantity of exhaled aerosols released into the environment during nebulisation. Pharmaceutics. 2019;11:1–9.
   Web of Science ®Google Scholar
• Gamage B, Moore D, Copes R, et al. Protecting health care workers from SARS and other respiratory pathogens: a review of the infection control literature. Am J Infect Control. 2005;33:88–96.
   Web of Science ®Google Scholar
• Hui DS, Chow BK, Chu LCY, et al. Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest. 2009;135:648–654.
   PubMed Web of Science ®Google Scholar
• Ibrahim E, Harnish D, Kinney K, et al. An experimental investigation of the performance of a Collison nebulizer generating H1N1 influenza aerosols. Biotechnol Biotechnol Equip. 2015;29:1142–1148.
   Web of Science ®Google Scholar
• Amirav I, Newhouse MT. Transmission of coronavirus by nebulizer: a serious, underappreciated risk. Can Med Assoc J. 2020;192:E346–E346.
   PubMed Web of Science ®Google Scholar
• GINA. No Title. FAQ Asthma COVID-19 2020. [cited 2020 Apr 14]. Available from: https://ginasthma.org/covid-19-gina-answers-to-frequently-asked-questions-on-asthma-management/
   Google Scholar
• Respaud R, Vecellio L, Diot P, et al. Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin Drug Deliv. 2015;12:1027–1039.
   PubMed Web of Science ®Google Scholar
• Pritchard JN, Hatley RHM, Denyer J, et al. Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments. Ther Deliv. 2018;9:121–136.
   PubMed Web of Science ®Google Scholar
• Zhang J, Dong X, Cao Y, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;all.14238. DOI:10.1111/all.14238.
   Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;1–13. DOI:10.1056/NEJMoa2001282.
   Web of Science ®Google Scholar
• Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3:722–727.
   PubMed Web of Science ®Google Scholar
• Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:1–10.
   PubMed Web of Science ®Google Scholar
• Colson P, Rolain JM, Lagier JC, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55:105932.
   PubMed Web of Science ®Google Scholar
• Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72–73.
   PubMed Web of Science ®Google Scholar
• Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients With COVID-19. Jama. 2020;18–19. DOI:10.1001/jama.2020.3633
   Web of Science ®Google Scholar
• Alhazzani W, Møller MH, Arabi YM. et al. surviving Sepsis Campaign: guideline on critically ill adults with Coronavirus Disease 2019 (COVID-19) Intensive Care Med. 2020,1–34.
   Google Scholar
• Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clin Infect Dis. 2019;68:895–902.
   PubMed Web of Science ®Google Scholar
• Ferguson ND, Fan E, Camporota L, et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med. 2012;38:1731–1732.
   Web of Science ®Google Scholar
• Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8:267–276.
   PubMed Web of Science ®Google Scholar
• Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368:2159–2168.
   PubMed Web of Science ®Google Scholar
• Meng L, Qiu H, Wan L, et al. Intubation and ventilation amid the COVID-19 outbreak: Wuhan’s experience. Anesthesiology. 2020. DOI:10.1097/ALN.0000000000003296.
   Web of Science ®Google Scholar
• Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;1–13. DOI:10.1056/NEJMoa2002032.
   PubMed Web of Science ®Google Scholar
• Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis. 2020;ciaa247. DOI:10.1093/cid/ciaa247.
   Web of Science ®Google Scholar
• Linscheid P, Seboek D, Nylen ES, et al. in vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology. 2003;144:5578–5584.
   PubMed Web of Science ®Google Scholar
• Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. Jama. 2020;4720:2019–2021.
   Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;2019:3–6.
   Google Scholar
• Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. Jama. 2020;1–7. DOI:10.1001/jama.2020.3204.
   Web of Science ®Google Scholar
• Bulletin ACCC. COVID-19 Clinical Guidance For the Cardiovascular Care Team; n.d..p. 1–4.
   Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor article SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:1–10.
   Web of Science ®Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;2600:1–7.
   Google Scholar
• van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as COMPARED with SARS-CoV-1. N Engl J Med. 2020 Mar 17. [Epub Ahead Print] PubMed PMID 32182409 n.d. DOI:10.1056/NEJMc2004973
   Web of Science ®Google Scholar
• Tellier R, Li Y, Cowling BJ, et al. Recognition of aerosol transmission of infectious agents: a commentary. BMC Infect Dis. 2019;19:1–9.
   PubMed Web of Science ®Google Scholar
• Jones RM, Brosseau LM. Aerosol transmission of infectious disease. J Occup Environ Med. 2015;57:501–508.
   PubMed Web of Science ®Google Scholar
• Cheung TMT, Yam LYC, So LKY, et al. Effectiveness of noninvasive positive pressure ventilation in the treatment of acute respiratory failure in severe acute respiratory syndrome. Chest. 2004;126:845–850.
   PubMed Web of Science ®Google Scholar
• Han F, Jiang -Y-Y, Zheng J-H, et al. [Acute respiratory failure and noninvasive positive pressure ventilation treatment in patients with severe acute respiratory syndrome]. Zhonghua Jie He He Hu Xi Za Zhi. 2004;27:593–597.
   Google Scholar
• Bausewein C, Currow DC, Johnson MJ, editors. Palliative care in respiratory disease. Eur Respir Soc. 2016. DOI:10.1183/2312508X.erm7316
   Google Scholar